Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bleeding problems in the cancer patient.

P J Rosen1

  • 1Division of Hematology/Oncology, University of California, School of Medicine, Los Angeles.

Hematology/Oncology Clinics of North America
|December 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer.

Cancer chemotherapy and pharmacology·2012
Same author

Low-dose trimetrexate glucuronate and protracted 5-fluorouracil infusion in previously untreated patients with advanced pancreatic cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2002
Same author

A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia.

Leukemia research·2000
Same author

A phase II trial of irinotecan in hormone-refractory prostate cancer.

Investigational new drugs·1999
Same author

Oncogenic osteomalacia associated with prostate cancer.

The Journal of urology·1997
Same author

Clinical characteristics predict response to antithymocyte globulin in paroxysmal nocturnal haemoglobinuria.

British journal of haematology·1997
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Cancer patients experience bleeding due to tumors affecting clotting or cancer treatments. These issues include disseminated intravascular coagulation and chemotherapy-induced thrombocytopenia, impacting patient health.

Area of Science:

  • Oncology
  • Hematology

Background:

  • Cancer patients frequently encounter bleeding complications.
  • These issues stem from both the malignancy and its treatments.

Purpose of the Study:

  • To review the causes and types of bleeding problems in cancer patients.
  • To differentiate between tumor-related and treatment-related bleeding disorders.

Main Methods:

  • Literature review of tumor-related and treatment-related bleeding complications.
  • Analysis of hemostatic mechanisms affected by cancer and its therapies.

Main Results:

  • Tumor-related bleeding includes disseminated intravascular coagulation, primary fibrinolysis, thrombocytopenia, platelet dysfunction, and anticoagulants.
  • Disseminated intravascular coagulation is linked to hypercoagulability in solid tumors but presents as bleeding in acute promyelocytic leukemia.

Related Experiment Videos

  • Treatment-related bleeding often involves thrombocytopenia from myelosuppressive chemotherapy and microangiopathic hemolytic anemia from agents like mitomycin C.

    • Conclusions:

    • Bleeding in cancer patients is multifactorial, arising from tumor-host interactions and therapeutic interventions.
    • Understanding these distinct causes is crucial for effective management and improved patient outcomes.